 |
Sobre Interferon Beta
- The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results. Neurology 1993; 43:655-661.
- Paty DW, li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. II. MRI analysis. Neurology 1993; 43:662-667.
- Jacobs LD, Cookfair DL, Rudick TA, et al. Intremuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.
- Rudick RA, Goodkin DE, jacobs LD, et al. The impact of interferon beta- 1a on nurologic disability in multiple sclerosis. Neurology 1997; 49:358-363.
- Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43:79-87.
- PRISMS Study Group. Randomised, double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
- European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-1497.
- Cross AH, Antel JP. Antibodies to beta-interferons in multiple sclerosis. Can we neutralize the controversy? Neurology 1998; 50:1206-1208.
- The Once Weekly Interferon for MS Group. Evidence of interferon beta-1a dose response in relapsing remitting MS. The OWIMS study. Neurology 1999; 53:679-686.
- Li DKB, Paty DW, UBC MS/MRI Analysis Reseaarch group, and the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Ann Neurol 1999; 46:197-206.
- Miller DH, Molyneux PD, barker GJ, et al. Effect of interferon beta-1b on magnetic resonance imaging aoutcomes in secondary progressive multiple sclerosis: Results of a European multicenter randomized double-blind placebo-controlled trial. Ann Neurol 1999; 46:850-859.
Sobre Glatiramer Acetato
- Johnson KP, brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter; double-blind, placebo-controlled trial. Neurology 1995; 45:1268-1276.
- Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of diasbility. Neurology 1998; 50:701-708.
Sobre Inmunoglobulinas intravenosas
- Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing remitting multiple sclerosis. Lancet 1997; 349:589-593.
- Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273-1281.
- Lisak RP. Intravenous immunoglobulins in multiple sclerosis. Neurology 1998; 51(Suppl):S25-S29.
Sobre Azatioprina
- Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051-1055.
Sobre Ciclofosfamida
- Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43:910-918.
- Noseworthy JH, Ebers GC, Gent M, et al. The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446.
Sobre Ciclosporina-A
- Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinicala trial. Ann Neurol 1990;591-605.
Sobre Metotrexate
- Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progreession in chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40.
Sobre Cladribina
- Rice GPA, for the Cladribine Clinical Study Group; and Filippi M and Comi GC, for the Cladribine MRI Study Group. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54:1145-1155.
Sobre Mitoxantrona
- Millefiorini E, Gasperini C, Pozzilli C, et al. Randomised placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: A 24-month clinical and MRI outcome. J Neurol 1997; 244:153-159.
- Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62:112-118.
Sobre Sulfasalazina
- Noseworthy JH, O’Brien P, Erickson BJ, et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998; 51:1342-1352.
Sobre Plasmaféresis
- Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-886.
Sobre Aciclovir
- Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996; 243:214-224.
Sobre tratamientos bajo desarrollo
- Hohfeld R. Biotechnological agents in the immunotherapy of multiple sclerosis. Brain 1997; 120:865-916.
|
